¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Ehrlich's phenomenon"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® rebound phenomenon ÇÑ±Û ¹Ý¹ßÇö»ó, ¹Ýµ¿Çö»ó
¼³¸í   
  ¼Ò³ú ±â´ÉÀå¾Ö¿¡¼­ »çÁöÀÇ ´ëÇ×±ÙÀ° »çÀÌÀÇ ÇùÁ¶¼º »ó½ÇÀǠ¡Èķμ­, È¯ÀÚ¿¡°Ô ¾çÆÈÀ» ¼öÆòÀ¸·Î »¸°Ô ÇÏ°í ±× ÆÈÀ» °­ÇϰԠġ¸é Á¤»óÀΠ°æ¿ì´Â °ð ¿ø»óÀ¸·Î ¿Ã¸®´Âµ¥ ºñÇÏ¿© È¯ÀÚ¿¡ À־´Â ¿øÀ§Ä¡·Î µ¹¾Æ¿À´Â µ¥ ¸î ¹øÀ̳ª ¶³°Ô µÈ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • aqueous-influx phenomenon
    ¹æ¼öÀ¯ÀÔÇö»ó
  • adoption phenomenon
    ä¿ëÇö»ó
  • clasp-knife phenomenon
    Á¢´ÂÄ®Çö»ó
  • closing-in phenomenon
    Á¾°áÇö»ó
  • critical phenomenon
    ÀÓ°èÇö»ó
  • crowding phenomenon
    ¹ÐÁýÇö»ó
  • cytopathogenic phenomenon
    ¼¼Æ÷º¯¼ºÇö»ó
  • centralization phenomenon
    Áß½ÉÈ­Çö»ó
  • duplication phenomenon
    º¹Á¦Çö»ó
  • delay phenomenon
    Áö¿¬Çö»ó
  • dawn phenomenon
    »õº®Çö»ó, ¿©¸íÇö»ó
  • discontinuity phenomenon
    ºÒ¿¬¼ÓÇö»ó
  • dissociative phenomenon
    ÇØ¸®Çö»ó
  • doll¡¯s head phenomenon
    ÀÎÇü¸Ó¸®Çö»ó
  • entoptic phenomenon
    ³»½ÃÇö»ó
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • phenomenon
    Çö»ó
  • phantom phenomenon
    ÇêÇö»ó, ȯ»óÇö»ó
  • rebound phenomenon
    ¹Ýµ¿Çö»ó
  • recruitment phenomenon
    Á¡ÁõÇö»ó, ´©°¡Çö»ó, º¸ÃæÇö»ó
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adoption phenomenon
    ä¿ëÇö»ó
  • aqueous-influx phenomenon
    ¹æ¼öÀ¯ÀÔÇö»ó
  • clasp-knife phenomenon
    Á¢´ÂÄ®Çö»ó
  • closing-in phenomenon
    Á¾°áÇö»ó
  • critical phenomenon
    ÀÓ°èÇö»ó
  • crowding phenomenon
    ¹ÐÁýÇö»ó
  • cytopathogenic phenomenon
    ¼¼Æ÷º¯¼ºÇö»ó
  • delay phenomenon
    Áö¿¬Çö»ó
  • discontinuity phenomenon
    ºÒ¿¬¼ÓÇö»ó
  • dissociative phenomenon
    ÇØ¸®Çö»ó
  • doll¡¯s head phenomenon
    ÀÎÇü¸Ó¸®Çö»ó
  • down phenomenon
    »õº®Çö»ó, ¿©¸íÇö»ó
  • duplication phenomenon
    º¹Á¦Çö»ó
  • entoptic phenomenon
    ³»½ÃÇö»ó
  • entry phenomenon
    ÁøÀÔÇö»ó
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Ehrlich reaction
    ¿¡¸£¸®È÷ ¹ÝÀÀ
  • Arthus phenomenon
    ¾Æ¸£Åõ½º Çö»ó(~ úÞßÚ)
  • Arthuss phenomenon
    ¾Æ¸£Åõ½ºÇö»ó
  • Bells phenomenon
    º§Çö»ó
  • CRST(Calcinosis, Raynauds phenomenon, Sclerodactyly, Telangiectasia) syndrome
    CRST ÁõÈıº.
  • Chameleon phenomenon
    Ä«¸á·¹¿ÂÇö»ó.
  • Danysz phenomenon
    Danysz Çö»ó
  • Danyszs phenomenon
    ´Ù´ÏÁî Çö»ó
  • Faraday s phenomenon
    ÆÐ·¯µ¥ÀÌÇö»ó.
  • Fowler phenomenon
    º¸ÃæÇö»ó
  • Gibbs phenomenon
    ±é½º Çö»ó
  • Gunns pupillary phenomenon
    °Ç¾¾µ¿°øÇö»ó
  • Hirsts phenomenon
    Ç㽺Ʈ Çö»ó
  • Jack-in-the-box phenomenon
    µ¹¿¬½ÃÇö»ó
  • Kanagawa hemolysis phenomenon
    Ä«³ª°¡¿Í ¿ëÇ÷Çö»ó (º´¿ø¼º ºñºê¸®¿ÀÀÇ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • lupus erythematosus phenomenon = LE phenomenon
    È«¹Ý¼º ·çǪ½ºÇö»ó(¡­úÞßÚ)
  • anamnestic phenomenon
    ±â¿ÕÇö»ó (¡­úÞßÚ).
  • anamnestic phenomenon
    ¸é¿ª[ÇÐÀû]±â¾ï[Çö»ó]
  • aqueous-influx phenomenon
    ¹æ¼öÀ¯ÀÔÇö»ó
  • arm phenomenon
    ÆÈ Çö»ó.
  • autoscopic phenomenon
    ÀÚ±âȯ¿µÇö»ó
  • blanching phenomenon
    â¹éÇö»ó(óïÛÜúÞßÚ).
  • blue-field entopic phenomenon
    û»ö½Ã¾ß³»½ÃÇö»ó
  • blush-and-blanch phenomenon
    È«Á¶Ã¢¹éÇö»ó(ûõðÍóïÛÜúÞßÚ).
  • break off phenomenon
    ÀÌÅ»°¨°¢Çö»ó(ìÆ÷­ÊïÊÆúÞßÚ)
  • break phenomenon
    ±úÁüÇö»ó, ÆÄ¿­Çö»ó
  • bulbar phenomenon
    ¿¬¼öÇö»ó.
  • cervicolumbar phenomenon
    °æ¿äÇö»ó(Ìòé¦úÞßÚ).
  • clasp knife phenomenon
    Á¢´Â Ä® Çö»ó
  • clasp-knife phenomenon
    Á¢´Â Ä® Çö»ó.
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Sarle's phenomenon
    »ì·¹Çö»ó
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Danysz phenomenon
    ´ë´ÏÁî Çö»ó(úÞßÚ)
  • ectrokinetic phenomenon
    °è¸éµ¿Àü±â Çö»ó(Í£ØüÔÑï³Ñ¨úÞßÚ)
  • plateau phenomenon
    Ç÷¡Åä Çö»ó(úÞßÚ)
  • Ehrlich ascites tumor
    ¿¡¸¦¸®È÷ º¹¼öÁ¾(ÜÙâ©ðþ)
  • Ehrlich reaction
    ¿¡¸¦¸®È÷ ¹ÝÀÀ(Úãëë)
  • Ehrlich's reagent
    ¿¡¸¦¸®È÷ ½Ã¾à(ãËå·)
  • Ehrlich's receptor theory
    ¿¡¸¦¸®È÷ ¼ö¿ëüÀÌ·Ð(áôé»ô÷×âÖå)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • entry phenomenon
    ÁøÀÔÇö»ó
  • entry slice phenomenon
    À¯ÀԴܸéÇö»ó
  • flare phenomenon
    Àå°³Çö»ó
  • Gibbs phenomenon
    ±é½ºÇö»ó
  • iceberg phenomenon
    ºù»ê Çö»ó
  • phenomenon
    Çö»ó
  • rebound phenomenon
    ¹Ýµ¿Çö»ó
  • slice entry phenomenon
    ÀýÆíÀÔ±¸Çö»ó
  • sunset phenomenon
    ÀϸôÇö»ó
  • time of flight phenomenon
    À¯Ã¼¼Óµµ°­Á¶Çö»ó
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
EAC Ehrlich ascites carcinoma; electroacupuncture; epithelioma adenoides cysticum; erythema annulare cen...
EAT Eating Attitudes Test; Ehrlich ascites tumor; electro-aerosol therapy; epidermolysis acuta toxica; e...
EATC Ehrlich ascites tumor cell
EU Ehrlich unit; elementary unit; emergency unit; endotoxin unit; entropy unit; enzyme unit; esterase u...
CREST Syndrome   1. Calcinosis cutis
  2. Raynaud's phenomenon
  3. Esophageal ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
PRP Primary Raynaud's Phenomenon
RP Raynaud Phenomenon
EA Ehrlich Ascites
EAC Ehrlich Ascites Carcinoma
EAT Ehrlich Ascites Tumor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Ehrlich`s side chain theory
    ¿¡¸¦¸®È÷ÀÇ Ãø¼â¼³
    Ç×ü »ý»ê ±âÀü¿¡ ´ëÇÏ¿© Á¦¾ÈµÈ °¡¼³ÀÇ Çϳª. ¸ðµç ü ¼¼Æ÷ Ç¥¸é¿¡´Â Ãø¼â¶ó°í ÇÏ´Â ¼ö¿ëü°¡ ÀÖ°í, À̰Ϳ¡ ´ëÀÀÇÏ´Â Ç׿øÀÌ °áÇÕÇϸé Ȱ¼ºÈ­ µÇ°í, Ãø¼â°¡ °úÀ× »ý»êµÇ¾î Ç×ü·Î¼­ Ç÷·ù ¼Ó¿¡ ¹æÃâµÈ´Ù°í ÇÏ´Â »ý°¢. Ç×ü »ý»êÀÇ ¼±Åü³ÀÇ ÃÖÃÊÀÇ °ÍÀÌ´Ù.
  • Heinz-Ehrlich body
    ÇÏÀÎÁî-¿¡¸¦¸®È÷¼Òü
    Ç÷»ö¼ÒÀÇ »êÈ­ Àå¾Ö¿Í ±× ħÀüÀ¸·Î »ý±ä ±¸»óÀÇ ºÀÀÔü·Î¼­, ¾î¶² Á¾·ùÀÇ ºñÁ¤»ó Ç÷»ö¼Ò ¹× È¿¼Ò °áÇÌ ÀûÇ÷±¸°¡ Á¸ÀçÇÒ ¶§ º¼ ¼ö ÀÖ´Ù. Ç÷¾× µµ¸» Ç¥º»¿¡¼­´Â ±¼Àý¼ºÀ̸ç Romanowsky ¿°»ö¹ýÀ¸·Î´Â ¿°»öµÇÁö ¾Ê°í, ÃÊ»ýü ¿°»ö¹ýÀ¸·Î ¿°»öµÈ´Ù.
  • aldosterone escape phenomenon
    ¾Ëµµ½ºÅ×·Ð ¹èÃâ Çö»ó
    ¼¼Æ÷ ¿Ü¾×ÀÌ ¾î´À Á¤µµ Áõ°¡Çϸé aldosteroneÀÇ ºÐºñ°¡ °è¼Ó Áõ°¡ÇÏ´õ¶óµµ ³ªÆ®·ýÀÇ ¹è¼³ÀÌ Áõ°¡ÇÏ´Â Çö»óÀ» ¸»ÇÑ´Ù. ÀÌ Çö»óÀº ¼¼Æ÷ ¿Ü¾×ÀÇ Áõ°¡¿Í ÀϺδ ANH
  • aqueous-influx phenomenon
    ¹æ¼ö À¯ÀÔ Çö»ó
  • arthus phenomenon
    ¾Æ¸£Æ©½º Çö»ó
  • central pain phenomenon
    ÁßÃß¼º µ¿Åë Çö»ó
  • Chiristensen phenomenon
    Å©¸®½ºÅÙ¼¾ Çö»ó
    ÇϾÇÀÇ Àü¹æ¿îµ¿ ½Ã ´ëÇÕÇÏ´Â ±³ÇÕ¸é »çÀÌ¿¡ »ý±â´Â °£°Ý.
  • Christensen's phenomenon
    Å©¸®½ºÅÙ¼¾ Çö»ó
  • Class Switching phenomenon
    ºÐ·ù Àüȯ Çö»ó
    ÇϳªÀÇ B ¼¼Æ÷°¡ ±×¿¡ »óÀÀÇÒ ¼ö Àִ ƯÀÌ Ç׿ø¿¡ Á¢ÇÏ¿´À» ¶§ isoty
  • dawn phenomenon
    »õº® Çö»ó
    Á¦ 1Çü ´ç´¢º´ ȯÀÚÀÇ 75%¿¡¼­, ±×¸®°í ´Ù¼öÀÇ Á¦ 2Çü ´ç´¢º´ ȯÀÚ ¹× Á¤»óÀο¡¼­µµ ÀϾ´Ù. À̰ÍÀº ¿ÀÀü 5-8½Ã »çÀÌ¿¡ Àν¶¸°¿¡ ´ëÇÑ Á¶Á÷ÀÇ °¨¼ö¼ºÀÌ °¨¼ÒÇÏ¿© ÀϾ´Ù. ÃÖ±ÙÀÇ Áõ°Å´Â ÀÌ Çö»óÀÌ ¼ö¸é Áß¿¡ ¼ºÀå È£¸£¸ó ºÐºñÀÇ Áõ°¡¿¡ ÀÇÇÏ¿© À¯¹ßµÇ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. »õº® Çö»óÀÌ ´Üµ¶À» ¹ß»ýÇϸé À̸¥ ¾ÆÄ§¿¡ °æµµÀÇ °íÇ÷´çÁõÀÌ ¿À³ª ¼Ò¸ð±â È¿°ú³ª °¨Åð Çö»óÀÌ µ¿¹ÝµÇ¸é °íÇ÷´çÁõÀº ½ÉÇØÁø´Ù.
  • dolls head phenomenon
    ÀÎÇü ¸Ó¸® Çö»ó, ÀÎÇü µÎ Çö»ó
  • flare phenomenon
    Àå°³ Çö»ó
  • Fowler phenomenon
    º¸Ãæ Çö»ó
  • iceberg phenomenon
    ºù»ê Çö»ó
  • jaw winking phenomenon
    ÅÎ-À®Å© Çö»ó
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
Ehrlich's phenomenon The difference between the amount of diphtheria toxin that will exactly neutralise one unit of antitoxin and that which, added to one unit of antitoxin, will leave one lethal dose free is greater than one lethal dose of toxin; i.e., it is necessary to add more than one lethal dose of toxin to a neutral mixture of toxin and antitoxin to make the mixture lethal (the basis of the L+ dose).
(05 Mar 2000)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
carcinoma, ehrlich tumour A transplantable, poorly differentiated malignant tumour which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.
(12 Dec 1998)
Paul Ehrlich <person> A brilliant scientist and student, born in Silesia, Germany, who at the age of 23 published his first scientific paper which was on the discovery of the mast cells - a name coined by him (1887). While a resident in medicine at Charite Hospital in Berlin he utilised the newly discovered aniline dyes to develop some of the basic methods of histology.
Among his contributions are: The preparation and staining of blood smears, he demonstrated granules in leukocytes, described the neutrophil, basophil, eosinophil, myelocyte, and mononuclear cells (white blood cells), he demonstrated normoblasts, megaloblasts and microblasts of the erythrocytic (red blood cell) series.
In 1887, he differentiated lymphocytic leukaemia from "bone marrow leukaemia" (myeloid) on blood smear, in 1888, he described aplastic anaemia, in 1882 the diazo reaction of typhoid urines, in 1882, less than six weeks after Koch described the Tuberculus bacillus, Ehrlich had described its acid-fastness and devised the fuchsin stain to demonstrate the pink rod on a blue background.
Ehrlich fell ill with tuberculosis and went to Egypt for 3 years for rest and cure. Following his return, he entered the field of immunology. at Von Behring's request, he developed means of standardising antitoxin dosage (immunization units).
at the age of 42, he became director of the "Royal Institute for Standardisation and Investigation of Antitoxic Sera." Here he devised his famous "side-chain" theory of immunisation. It has since been replaced.
Paul Ehrlich reinvestigated Bordet's alexin and heat-stable substance and named them "complement" and "immune body". Ehrlich coined the terms and created a new science of chemotherapy.
In 1910 he discovered Salvarsan or 606, a therapeutic antiluetic. For his silver bullet (Salvarsan) in 1908, he received the Nobel Prize. This scientist was greatly concerned over the problem of drug fastness which still remains a problem. He died August 20, 1915.
Lived: 1854-1915.
(18 Nov 1997)
Heinz-Ehrlich body A round oxyphil body found in the red blood cell in case of haemocytolysis due to a specific blood poison.
Synonym: Heinz-Ehrlich body.
(05 Mar 2000)
Ehrlich Paul, German bacteriologist, immunologist, and Nobel laureate, 1854-1915.
See: Ehrlichia, Ehrlich's anaemia, Ehrlich's inner body, Ehrlich's phenomenon, Ehrlich's postulate, Ehrlich's diazo reagent, Ehrlich's theory, Ehrlich-Turk line. See entries under stain; reaction.
(05 Mar 2000)
Ehrlich, Paul <person> A brilliant scientist and student, born in Silesia, Germany, who at the age of 23 published his first scientific paper which was on the discovery of the mast cells - a name coined by him (1887). While a resident in medicine at Charite Hospital in Berlin he utilised the newly discovered aniline dyes to develop some of the basic methods of histology.
Among his contributions are: The preparation and staining of blood smears, he demonstrated granules in leukocytes, described the neutrophil, basophil, eosinophil, myelocyte, and mononuclear cells (white blood cells), he demonstrated normoblasts, megaloblasts and microblasts of the erythrocytic (red blood cell) series.
In 1887, he differentiated lymphocytic leukaemia from "bone marrow leukaemia" (myeloid) on blood smear, in 1888, he described aplastic anaemia, in 1882 the diazo reaction of typhoid urines, in 1882, less than six weeks after Koch described the Tuberculus bacillus, Ehrlich had described its acid-fastness and devised the fuchsin stain to demonstrate the pink rod on a blue background.
Ehrlich fell ill with tuberculosis and went to Egypt for 3 years for rest and cure. Following his return, he entered the field of immunology. at Von Behring's request, he developed means of standardising antitoxin dosage (immunization units).
at the age of 42, he became director of the "Royal Institute for Standardisation and Investigation of Antitoxic Sera." Here he devised his famous "side-chain" theory of immunisation. It has since been replaced.
Paul Ehrlich reinvestigated Bordet's alexin and heat-stable substance and named them "complement" and "immune body". Ehrlich coined the terms and created a new science of chemotherapy.
In 1910 he discovered Salvarsan or 606, a therapeutic antiluetic. For his silver bullet (Salvarsan) in 1908, he received the Nobel Prize. This scientist was greatly concerned over the problem of drug fastness which still remains a problem. He died August 20, 1915.
Lived: 1854-1915.
(18 Nov 1997)
Ehrlich reaction The reaction of the indole derivatives with aromatic aldehydes; e.g., tryptophan and p-dimethylaminobenzaldehyde in H2SO4 give a red-violet colour useful in assaying proteins for tryptophan content.
Synonym: Ehrlich reaction.
(05 Mar 2000)
Ehrlich's acid haematoxylin stain <technique> An alum type of haematoxylin stain used as a regressive staining method for nuclei, followed by differentiation to required staining intensity; the solution may be allowed to ripen naturally in sunlight or partially oxidised with sodium iodate.
(05 Mar 2000)
Ehrlich's anaemia <haematology> This form of anaemia occurs when the bone marrow ceases sufficient red and white blood cell production. It may be induced by exposures to high levels of toxic chemicals, radiation and certain drugs.
It is generally unresponsive to specific therapy, often accompanied by granulocytopenia and thrombocytopenia, in which the bone marrow may not necessarily be hypocellular or hypoplastic but fails to produce adequate numbers of peripheral blood elements. The term actually is all inclusive and most probably encompasses several clinical syndromes.
Origin: Gr. Haima = blood
(29 Sep 1997)
Ehrlich's aniline crystal violet stain <technique> A stain for Gram-positive bacteria.
(05 Mar 2000)
Ehrlich's benzaldehyde reaction A test for urobilinogen in the urine, by dissolving 2 g of dimethyl-p-aminobenzaldehyde in 100 ml of 5% hydrochloric acid and adding this reagent to urine; a red colour in the cold indicates the presence of an excessive amount of urobilinogen.
(05 Mar 2000)
Ehrlich's diazo reaction The reaction of diazotised sulfanilic acid with bilirubin to form azobilirubin, which forms the basis of quantitating the amount of bilirubin in biological fluids.
See: van den Bergh's test.
Synonym: Ehrlich's diazo reaction.
(05 Mar 2000)
Ehrlich's diazo reagent Two solutions, one of sodium nitrite, the other of acidified sulfanilic acid, used in bringing about diazotization.
Synonym: Ehrlich's diazo reagent.
(05 Mar 2000)
Ehrlich's inner body A round oxyphil body found in the red blood cell in case of haemocytolysis due to a specific blood poison.
Synonym: Heinz-Ehrlich body.
(05 Mar 2000)
Ehrlich's postulate Ehrlich postulated that cells contained surface extensions or side chains (haptophores) that bind to the antigenic determinants of a toxin (toxophores); after a cell is stimulated, the haptophores are released into the circulation and become the antibodies.
See: receptor.
Synonym: Ehrlich's postulate.
(05 Mar 2000)
Ehrlich's theory Ehrlich postulated that cells contained surface extensions or side chains (haptophores) that bind to the antigenic determinants of a toxin (toxophores); after a cell is stimulated, the haptophores are released into the circulation and become the antibodies.
See: receptor.
Synonym: Ehrlich's postulate.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • phenomenon
    »ç°Ç; Çö»ó
  • Raynaud's phenomenon
    ·¹À̳ë Çö»ó(¼ÕÀÇ ¼Òµ¿¸Æ ¼öÃà¿¡ ÀÇÇÑ ÀϽÃÀû Ç÷¾× ºÎÁ·À¸·Î ¼Õ°¡¶ô.¼ÕÀÇ ÀϺΰ¡ â¹éÇØ Áö´Â Çö»ó)
  • dellinger phenomenon
    µ¨¸°Àú Çö»ó 9
  • phenomenon
    Çö»ó;°æÀÌ;Áø±âÇÑ »ç¹°
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á